Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO-B
NCT03997383Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 22
01
Overview
A Phase 3 trial of patisiran in transthyretin amyloidosis (ATTR), sponsored by Alnylam Pharmaceuticals. Started Sep 2019; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT03997383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997383.